Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether | 148081-69-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether
• 英文别名: 3-Hydroxy-6-butyloxy-1.2.4-trimethyl-benzol；4-Butyloxy-2.3.6-trimethyl-phenol；4-Butoxy-2,3,6-trimethyl-phenol；Phenol, 4-butoxy-2,3,6-trimethyl-；4-butoxy-2,3,6-trimethylphenol
• CAS: 148081-69-0
• 化学式: C₁₃H₂₀O₂
• 分子量: 208.301
• InChiKey: MYRYIFIFOOHOBP-UHFFFAOYSA-N

物化性质

• 沸点：
  327.7±37.0 °C(Predicted)
• 密度：
  0.990±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether 在 sodium methylate 、 四氯化锡 作用下， 以 苯 为溶剂， 生成 (2R,3S,4S,5S,6R)-2-(4-butoxy-2,3,6-trimethylphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
  参考文献：
  名称：

  Inhibitory Effects of (4-Alkoxy-2,3,6-trimethylphenyl)glycopyranosides on Histamine Release Induced by Antigen-Antibody Reaction.

  摘要：

  检测了新合成的4-烷氧基-2,3,6-三甲基苯基D-吡喃糖苷对由抗原-抗体反应引起的组胺释放的抑制作用。在测试的化合物中,4-己氧基-2,3,6-三甲基苯基α-D-甘露糖吡喃糖苷表现出最强的抑制作用。此外,4-己氧基-2,3,6-三甲基苯基α-D-吡喃葡糖苷和α-D-吡喃半乳糖苷显著抑制抗原诱导的组胺释放,且它们的活性强于相应的β-异构体。这些结果表明这些化合物可能具有优秀的抗过敏活性。

  DOI：

  10.1248/cpb.42.1002
• 作为产物：
  描述：

  三甲基氢醌 、 正丁醇 在 phosphomolybdic acid 作用下， 反应 6.0h， 以73%的产率得到Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether
  参考文献：
  名称：

  Synthesis of 4-Alkoxyaryl .BETA.-D-Glucopyranosides and Their Inhibitory Effects on Histamine Release from Rat Peritoneal Mast Cells Induced by Concanavalin A.

  摘要：

  研究了新合成的4-烷氧基苯基β-D-葡萄糖苷对刀豆球蛋白A诱导的大鼠腹腔肥大细胞组胺释放的抑制作用。将疏水性（k'）与化合物的抑制活性作图，显示出明显的最大值，其中4-癸氧基-2,3,6-三甲基苯基β-D-葡萄糖苷在测试的化合物中是最有效的抑制剂。

  DOI：

  10.1248/cpb.42.570

文献信息

• Synthesis and Anti Lipid-Peroxidation Activity of Hydroquinone Monoalkyl Ethers.
  作者：Yasunori NIHRO、Haruhiro FURUKAWA、Satoshi SOGAWA、Tzer Chuan WANG、Hideki MIYATAKA、Hitoshi MATSUMOTO、Tokutaro MIKI、Toshio SATOH

  DOI：10.1248/cpb.42.576

  日期：——

  series of hydroquinone monoalkyl ethers was synthesized and evaluated for anti lipid-peroxidation activity in rat liver microsomes. 4-Hexyloxy-2,3,6-trimethylphenol (9), having a low redox potential, as well as ascorbic acid exhibited the strongest anti lipid-peroxidation activity (IC50 = 4.2 x 10(-7) M). Structure-activity relationship studies demonstrated that the inhibitory effect of hydroquinone monoalkyl

  合成了一系列氢醌单烷基醚，并评估了其在大鼠肝微粒体中的抗脂质过氧化活性。氧化还原电位低的4-己氧基-2,3,6-三甲基苯酚（9）以及抗坏血酸表现出最强的抗脂质过氧化活性（IC50 = 4.2 x 10（-7）M）。结构活性关系研究表明，对苯二酚单烷基醚对脂质过氧化的抑制作用通过获得最佳疏水性而增加，而由于疏水性不足或过度而降低。
• Assessing doctors' competence: application of CUSUM technique in monitoring doctors' performance
  作者：T. O. LIM、A. SORAYA、L. M. DING、Z. MORAD

  DOI：10.1093/oxfordjournals.intqhc.a002616

  日期：2002.6.1

  Background. Quality assurance of medical practice requires assessment of doctors’ performance, whether informally via a system such as peer review or more formally via one such as credentialing. Current methods of assessment are, however, subjective or implicit. More objective methods of assessment based on statistical process control technique such as cumulative sum procedure (CUSUM) may be helpful. Objective. To determine the usefulness and acceptability of CUSUM charting for assessing doctors’ performance. Method. We applied CUSUM charting to assess doctors’ performance of endoscopic retrograde pancreatography, renal and breast biopsies, thyroidectomy, and instrumental delivery. A CUSUM chart is a graphical representation of the trend in the outcome of a series of consecutive procedures. At acceptable levels of performance, the CUSUM curve is flat, while at unacceptable levels of performance, the curve slopes upward and eventually crosses a decision interval. When this occurs, the CUSUM chart indicates unsatisfactory performance. Thus, it provides an early warning of an adverse trend. Results. All participating doctors found the technique useful to objectively measure their proficiency. CUSUM charts showed the progress of trainees in acquiring new skills. As they become more skilful with training, their CUSUM curves flatten. Among consultants, level CUSUM curves demonstrated ongoing maintenance of competence. All participants found the technique acceptable as a self-assessment tool. They were, however, less certain of its acceptability as a basis for credentialing. Conclusion. We recommend the use of CUSUM charting as a tool for personal audit at an individual level. It may also be used to show proof of technical competence for the purpose of credentialing.

  背景。要保证医疗质量，就必须对医生的工作表现进行评估，无论是通过同行评议等非正式制度，还是通过资格认证等正式制度。然而，目前的评估方法都是主观或隐含的。基于统计过程控制技术（如累积总和程序）的更客观的评估方法可能会有所帮助。目标。确定 CUSUM 图表在评估医生绩效方面的实用性和可接受性。方法。我们应用 CUSUM 图表评估医生在内镜逆行胰腺造影术、肾脏和乳腺活组织检查、甲状腺切除术和器械接生中的表现。CUSUM 图表是一系列连续手术结果趋势的图形表示。在可接受的绩效水平下，CUSUM 曲线是平的，而在不可接受的绩效水平下，曲线会向上倾斜并最终越过决策区间。当出现这种情况时，CUSUM 图表就会显示出不理想的绩效。因此，它提供了不利趋势的预警。结果所有参与调查的医生都认为这项技术有助于客观衡量他们的工作能力。CUSUM 图表显示了学员在掌握新技能方面取得的进步。随着受训医生的技能不断提高，他们的 CUSUM 曲线也逐渐趋于平缓。在顾问中，水平 CUSUM 曲线显示了能力的持续保持。所有参与者都认为，该技术作为一种自我评估工具是可以接受的。不过，他们不太确定该技术是否可作为资格认证的依据。结论我们建议使用 CUSUM 图表作为个人层面的个人审核工具。它还可用于证明技术能力，以便进行资格认证。
• Curative drug for neurodegenerative diseases
  申请人：NIPPON HYPOX LABORATORIES INCORPORATED

  公开号：EP2052719A1

  公开（公告）日：2009-04-29

  A compound is prepared based on Formula 1: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared principally from the compound or a hydroquinone derivative consisting of a cyclodextrin inclusion compound thereof. The curative drug for neurodegenerative diseases has a safe and beneficial effect of inhibiting nerve cell disorder due to oxidative stress, thereby to stop progression of symptoms. The diseases include Alzheimer's and Parkinson's disease.

  根据式 1 制备化合物： 其中，R1 代表碳原子数为 4 至 8 的烷基，R2 代表氢原子、碳原子数为 2 至 6 的烷基羰基或碳原子数为 2 至 6 的烷氧羰基。治疗神经退行性疾病的药物可主要由该化合物或由其环糊精包合物组成的氢醌衍生物制备。这种治疗神经退行性疾病的药物具有安全有益的效果，可抑制氧化应激导致的神经细胞紊乱，从而阻止症状的发展。这些疾病包括阿尔茨海默病和帕金森病。
• Hepatic Fibrosis Inhibitor
  申请人：NIPPON HYPOX LABORATORIES INCORPORATED

  公开号：EP2110127A1

  公开（公告）日：2009-10-21

  The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.

  含有由以下化学式表示的化合物的肝纤维化抑制剂可抑制由慢性肝炎等各种肝病和肝损伤引起的肝纤维化和肝硬化的进展： 其中，R1 代表碳数为 4 至 8 的烷基，R2 代表氢原子、碳数为 2 至 6 的烷基羰基或碳数为 2 至 6 的烷氧羰基。
• CHRONIC RESPIRATORY DISEASE THERAPEUTIC AGENT AND CARDIAC FIBRILLATION SUPPRESSING COMPOSITION
  申请人：NIPPON HYPOX LABORATORIES INCORPORATED

  公开号：EP3287128A1

  公开（公告）日：2018-02-28

  A novel agent which is effective in the prevention or treatment of a chronic respiratory disease such as COPD, interstitial pneumonia and asthma is provided. The therapeutic agent for a chronic respiratory disease comprises, as an active ingredient, a hydroquinone derivative represented by general formula (1) wherein R1 represents an alkyl group having 4 to 8 carbon atoms, and R2 represents a hydrogen atom, an alkylcarbonyl group having 2 to 6 carbon atoms or an alkoxycarbonyl group having 2 to 6 carbon atoms.

  本发明提供了一种新型制剂，可有效预防或治疗慢性阻塞性肺病、间质性肺炎和哮喘等慢性呼吸道疾病。该慢性呼吸道疾病治疗剂包括通式（1）代表的氢醌衍生物作为活性成分，其中 R1 代表具有 4 至 8 个碳原子的烷基，R2 代表氢原子、具有 2 至 6 个碳原子的烷基羰基或具有 2 至 6 个碳原子的烷氧基羰基。